| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8605675 | Journal of Pain and Symptom Management | 2018 | 24 Pages |
Abstract
The MCID of the MFSI-SF identified by all approaches ranged from 4.50 to 10.79 points. The MCID can be used to interpret the clinical significance of fatigue deterioration in patients with breast cancer and to determine sample sizes for future clinical trials.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Alexandre PharmD, MPH, Tiffany Eri Yo, Xiao Jun PhD, Terence PhD, Jung-Woo PhD, Hui Ling Yeo, Maung Shwe, Yan Xiang Gan,